Cybin Inc.

NYSE American CYBN

Cybin Inc. Free Cash Flow Yield on December 30, 2024: -40.28%

Cybin Inc. Free Cash Flow Yield is -40.28% on December 30, 2024, a -157.97% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Cybin Inc. 52-week high Free Cash Flow Yield is -12.93% on March 15, 2024, which is 67.89% above the current Free Cash Flow Yield.
Cybin Inc. 52-week low Free Cash Flow Yield is -42.24% on October 03, 2024, which is -4.88% below the current Free Cash Flow Yield.
Cybin Inc. average Free Cash Flow Yield for the last 52 weeks is -27.02%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NYSE American: CYBN

Cybin Inc.

CEO	Mr. Douglas L. Drysdale
IPO Date	Sept. 13, 2019
Location	Canada
Headquarters	100 King Street West
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Key trends

Past 5 years